Product Description
Alumis is developing ESK-001 as a treatment for Plaque Psoriasis. (Sourced from: https://www.alumis.com/alumis-announces-initiation-of-patient-dosing-in-phase-2-clinical-trial-of-esk-001-for-the-treatment-of-plaque-psoriasis/)
Mechanisms of Action: Allosteric TYK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Alumis
Company Location: Western America
Company Founding Year: 2021
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Israel, Japan, Latvia, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 15
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Alumis announced they will present P2 Lupus Erythematosus, Systemic results in 3Q26 for Envudeucitinib
- Clinical Outcomes Expected - Alumis announced they will present P3 Psoriasis results in 2H26 for Envudeucitinib
- Clinical Outcomes Reported - Alumis presented P3 Psoriasis results on 2026-03-28 for Envudeucitinib
Highest Development Phases
Phase 3: Psoriasis|Pustular Psoriasis
Phase 2: Lupus Erythematosus, Systemic
Phase 1: Healthy Volunteers|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05739435 |
ESK-001-007 | P2 |
Active, not recruiting |
Psoriasis |
2026-12-01 |
56% |
2026-04-02 |
Primary Endpoints|Treatments |
jRCT2071260031 |
jRCT2071260031 | P3 |
Recruiting |
Pustular Psoriasis |
2028-06-30 |
|||
NCT05966480 |
LUMUS | P2 |
Active, not recruiting |
Lupus Erythematosus, Systemic |
2026-06-23 |
63% |
2026-07-22 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT06962774 |
ESK-001-023 | P1 |
Completed |
Kidney Diseases |
2025-08-01 |
2025-12-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
2023-507193-40-00 |
ESK-001-016 | P3 |
Recruiting |
Psoriasis |
2026-06-30 |
2025-05-02 |
Treatments |
|
jRCT2061250042 |
jRCT2061250042 | P3 |
Recruiting |
Psoriasis |
2028-11-15 |
|||
2024-511166-36-00 |
ESK-001-018 | P3 |
Not yet recruiting |
Psoriasis |
2028-11-15 |
2025-05-01 |
Treatments |
|
NCT06846541 |
ONWARD3 | P3 |
Active, not recruiting |
Psoriasis |
2028-11-01 |
9% |
2026-02-26 |
Primary Endpoints|Treatments|Trial Status |
jRCT2051240267 |
jRCT2051240267 | P3 |
Recruiting |
Psoriasis |
2026-10-14 |
|||
2023-508959-39-00 |
ESK-001-017 | P3 |
Recruiting |
Psoriasis |
2026-06-30 |
2025-05-02 |
Treatments |
|
NCT06588738 |
ONWARD2 | P3 |
Completed |
Psoriasis |
2025-09-23 |
4% |
2026-04-14 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06586112 |
ONWARD1 | P3 |
Completed |
Psoriasis |
2025-09-19 |
4% |
2026-04-14 |
Primary Endpoints |
NCT06952634 |
ESK-001-022 | P1 |
Completed |
Healthy Volunteers |
2026-03-24 |
2026-05-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT07378579 |
ESK-001-019 | P1 |
Completed |
Healthy Volunteers |
2024-08-31 |
2026-01-31 |
||
2022-002633-34 |
2022-002633-34 | P2 |
Active, not recruiting |
Psoriasis |
2023-10-07 |